27633393|t|Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study
27633393|a|There is limited knowledge on the short-term influence of radiofrequency ablation (RFA) of atrial fibrillation (AF) on 2 cardiac biomarkers; the N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the midregional fragment of the N-terminal of pro-ANP (MR-proANP) and 2 extracardiac biomarkers; the c-terminal provasopressin (copeptin) and the midregional portion of proadrenomedullin (MR-proADM). There are also limited data concerning cardiac production of the latter two. We studied 192 consecutive patients eligible for RFA of AF referred to the University Hospital, Linköping, Sweden. NT-proBNP, MR-proANP, copeptin, and MR-proADM levels were measured in peripheral blood, the coronary sinus (CS), and the left atrium before ablation, and in peripheral blood immediately and the day after RFA. The level of NT-proBNP decreased the day after RFA in participants in AF at the time of RFA, compared to the participants in sinus rhythm who showed a slight increase (P<0.001). Furthermore, regardless of the actual rhythm, the level of MR-proANP showed an increase immediately after RFA (P<0.001), followed by a decrease the day after ablation (P<0.001). Copeptin level showed a 6-fold increase immediately after RFA compared to baseline (P<0.001), whereas MR-proADM level increased the day after RFA (P<0.001). Levels of copeptin and MR-proADM were not higher in the CS compared to peripheral blood. RFA of AF is a strong stimulus with a significant and direct impact on different neurohormonal systems. We found no sign of a cardiac release of MR-proADM or copeptin. URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01553045.
27633393	0	10	Short-Term	T079	C0443303
27633393	24	47	Radiofrequency Ablation	T061	C0850292
27633393	51	60	NT-proBNP	T116,T123	C0754710
27633393	62	71	MR-proANP	T116,T123	C2975328
27633393	73	81	Copeptin	T116,T123	C3489439
27633393	87	96	MR-proADM	T116,T123	C3493807
27633393	100	108	Patients	T101	C0030705
27633393	114	133	Atrial Fibrillation	T047	C0004238
27633393	149	174	Observational SMURF Study	T062	C1518527
27633393	209	219	short-term	T079	C0443303
27633393	233	256	radiofrequency ablation	T061	C0850292
27633393	258	261	RFA	T061	C0850292
27633393	266	285	atrial fibrillation	T047	C0004238
27633393	287	289	AF	T047	C0004238
27633393	296	314	cardiac biomarkers	T201	C2735102
27633393	320	361	N-terminal pro-B-type natriuretic peptide	T116,T123	C0754710
27633393	363	372	NT-proBNP	T116,T123	C0754710
27633393	382	431	midregional fragment of the N-terminal of pro-ANP	T116,T123	C2975328
27633393	433	442	MR-proANP	T116,T123	C2975328
27633393	450	473	extracardiac biomarkers	T201	C2735102
27633393	479	504	c-terminal provasopressin	T116,T121	C0056279
27633393	506	514	copeptin	T116,T121	C0056279
27633393	524	564	midregional portion of proadrenomedullin	T116,T123	C3493807
27633393	566	575	MR-proADM	T116,T123	C3493807
27633393	617	624	cardiac	T023	C0018787
27633393	682	690	patients	T101	C0030705
27633393	704	707	RFA	T061	C0850292
27633393	711	713	AF	T047	C0004238
27633393	730	749	University Hospital	T073,T093	C0020028
27633393	751	768	Linköping, Sweden	T083	C0038995
27633393	770	779	NT-proBNP	T116,T123	C0754710
27633393	781	790	MR-proANP	T116,T123	C2975328
27633393	792	800	copeptin	T116,T123	C3489439
27633393	806	815	MR-proADM	T116,T123	C3493807
27633393	816	822	levels	T080	C0441889
27633393	840	856	peripheral blood	T031	C0229664
27633393	862	876	coronary sinus	T023	C0456944
27633393	878	880	CS	T023	C0456944
27633393	891	902	left atrium	T023	C0225860
27633393	910	918	ablation	T061	C0547070
27633393	927	943	peripheral blood	T031	C0229664
27633393	974	977	RFA	T061	C0850292
27633393	983	988	level	T080	C0441889
27633393	992	1001	NT-proBNP	T116,T123	C0754710
27633393	1002	1011	decreased	T081	C0205216
27633393	1026	1029	RFA	T061	C0850292
27633393	1033	1045	participants	T098	C0679646
27633393	1049	1051	AF	T047	C0004238
27633393	1067	1070	RFA	T061	C0850292
27633393	1088	1100	participants	T098	C0679646
27633393	1104	1116	sinus rhythm	T033	C0232201
27633393	1137	1145	increase	T169	C0442805
27633393	1188	1201	actual rhythm	T042	C0232187
27633393	1207	1212	level	T080	C0441889
27633393	1216	1225	MR-proANP	T116,T123	C2975328
27633393	1263	1266	RFA	T061	C0850292
27633393	1292	1300	decrease	T081	C0205216
27633393	1315	1323	ablation	T061	C0547070
27633393	1335	1349	Copeptin level	T059	C4284455
27633393	1393	1396	RFA	T061	C0850292
27633393	1409	1417	baseline	T081	C1442488
27633393	1437	1446	MR-proADM	T116,T123	C3493807
27633393	1447	1452	level	T080	C0441889
27633393	1453	1462	increased	T169	C0442805
27633393	1477	1480	RFA	T061	C0850292
27633393	1492	1498	Levels	T080	C0441889
27633393	1502	1510	copeptin	T116,T121	C0056279
27633393	1515	1524	MR-proADM	T116,T123	C3493807
27633393	1548	1550	CS	T023	C0456944
27633393	1563	1579	peripheral blood	T031	C0229664
27633393	1581	1584	RFA	T061	C0850292
27633393	1588	1590	AF	T047	C0004238
27633393	1603	1611	stimulus	T067	C0234402
27633393	1662	1683	neurohormonal systems	T125	C0597049
27633393	1694	1701	no sign	T033	C0311392
27633393	1707	1714	cardiac	T023	C0018787
27633393	1726	1735	MR-proADM	T116,T123	C3493807
27633393	1739	1747	copeptin	T116,T121	C0056279